Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
![Teva- Pharmaceutical Industries logo](/files/LOGO/818686-TEVA.png)
Company profile
Ticker
TEVA, TEVA-MM
Exchange
Website
CEO
Kaare Schultz
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
SEC CIK
Corporate docs
Subsidiaries
Actavis Group • Actavis International Limited • Actavis U.K. Group Ltd. • Arrow International Limited • Mepha Schweiz AG • Merckle GmbH • Pliva Hrvatska d.o.o. • Ratiopharm GmbH • Salomon, Levin & Elstein Ltd. • Teva API B.V. ...
TEVA stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
25 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
6 Jun 24
SD
Conflict minerals disclosure
30 May 24
8-K
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
15 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
8 May 24
8-K
Regulation FD Disclosure
18 Apr 24
DEFA14A
Additional proxy soliciting materials
16 Apr 24
ARS
2023 FY
Annual report to shareholders
16 Apr 24
DEF 14A
Definitive proxy
16 Apr 24
Transcripts
TEVA
Earnings call transcript
2023 Q2
2 Aug 23
TEVA
Earnings call transcript
2023 Q1
10 May 23
TEVA
Earnings call transcript
2022 Q4
8 Feb 23
TEVA
Earnings call transcript
2022 Q2
27 Jul 22
TEVA
Earnings call transcript
2022 Q2
27 Jul 22
TEVA
Earnings call transcript
2022 Q1
3 May 22
TEVA
Earnings call transcript
2021 Q4
9 Feb 22
TEVA
Earnings call transcript
2021 Q3
27 Oct 21
TEVA
Earnings call transcript
2021 Q2
28 Jul 21
TEVA
Earnings call transcript
2021 Q1
28 Apr 21
Latest ownership filings
4
ROBERTO MIGNONE
21 Jun 24
144
Notice of proposed sale of securities
18 Jun 24
4
Tal Zvi Zaks
17 Jun 24
4
ROBERTO MIGNONE
17 Jun 24
4
Rosemary A Crane
17 Jun 24
4
Ronit Satchi-Fainaro
17 Jun 24
4
Perry Nisen
17 Jun 24
4
Janet S. Vergis
17 Jun 24
4
GERALD M LIEBERMAN
17 Jun 24
4
Amir Elstein
17 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.99 bn | 2.99 bn | 2.99 bn | 2.99 bn | 2.99 bn | 2.99 bn |
Cash burn (monthly) | 78.67 mm | (no burn) | 72.67 mm | (no burn) | 41.33 mm | (no burn) |
Cash used (since last report) | 304.14 mm | n/a | 280.94 mm | n/a | 159.80 mm | n/a |
Cash remaining | 2.69 bn | n/a | 2.71 bn | n/a | 2.83 bn | n/a |
Runway (months of cash) | 34.2 | n/a | 37.3 | n/a | 68.5 | n/a |
Institutional ownership, Q1 2024
54.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 463 |
Opened positions | 397 |
Closed positions | 12 |
Increased positions | 21 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 6.83 tn |
Total shares | 616.57 mm |
Total puts | 13.68 mm |
Total calls | 19.76 mm |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Europacific Growth Fund | 52.75 mm | $813.41 mm |
BLK Blackrock | 43.70 mm | $616.67 bn |
Ion Asset Management | 38.58 mm | $544.34 bn |
PXGPE Phoenix | 34.58 mm | $488.08 bn |
Migdal Insurance & Financial | 29.86 mm | $421.29 mm |
Clal Insurance Enterprises | 28.79 mm | $406.06 mm |
Menora Mivtachim | 28.13 mm | $396.90 bn |
Slate Path Capital | 26.90 mm | $379.51 bn |
Exor Investments | 26.42 mm | $372.85 bn |
FMR | 21.25 mm | $299.82 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Jun 24 | Mignone Roberto | Ordinary Shares | Sell | Dispose S | Yes | No | 17.03 | 519,000 | 8.84 mm | 981,000 |
15 Jun 24 | Barer Sol J | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 37,598 | 0.00 | 409,114 |
15 Jun 24 | Barer Sol J | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 37,598 | 0.00 | 0 |
15 Jun 24 | Elstein Amir | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 21,108 | 0.00 | 2,094,331 |
15 Jun 24 | Elstein Amir | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 21,108 | 0.00 | 0 |
15 Jun 24 | Lieberman Gerald M | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 21,108 | 0.00 | 106,025 |
15 Jun 24 | Lieberman Gerald M | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 21,108 | 0.00 | 0 |
15 Jun 24 | Vergis Janet S. | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 21,108 | 0.00 | 64,065 |
15 Jun 24 | Vergis Janet S. | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 21,108 | 0.00 | 0 |
News
Teva And Sanofi Fast-Track Anti-TL1A Phase 2b Trial For Inflammatory Bowel Disease
25 Jul 24
Why Hims & Hers Heath Shares Are Surging Today
22 Jul 24
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
19 Jul 24
Teva's Migraine Treatment Found Effective For Children As Young As 6
18 Jul 24
Teva SPACE Pediatric Phase 3 Study Met Its Primary End Point For Efficacy With A Significantly Greater Reduction In Monthly Migraine Days Compared To Placebo; Efficacy Is Consistent With AJOVY Pivotal Phase 3 And Real-World Evidence Studies In Adults With No New Emergent Safety Signals Observed
18 Jul 24
Press releases
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
25 Jul 24
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
18 Jul 24
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
2 Jul 24
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
4 Jun 24
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
1 Jun 24